0.23
0.23 (0%)
As of Nov 08, 2023
Contrafect Corp [CFRX]
Source:
Company Overview
We are a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. We believe DLAs are fundamentally different than antibiotics and offer a potential paradigm shift in the treatment of antibiotic-resistant infections.
| Country | United States |
| Headquarters | yonkers, new york |
| Phone Number | 914-207-2300 |
| Industry | manufacturing |
| CEO | Roger J. Pomerantz, M.D., F.A.C.P. |
| Website | www.contrafect.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-6.7 |
| Net Income | $-5.4 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -36% |
| Profit as % of Stockholder Equity | 93.1% |
Management Effectiveness
| Return on Equity | 93.1% |
| Return on Assets | -58.7% |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.1 |
| Total Liabilities | $14.9 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | $0 |
| Financing Cash Flow | $0 |
